Abstract: A method for determining reflectivity of a tear film lipid layer of a patient and recommending a course of treatment based on the same. The method includes the steps of: measuring a tear film aqueous plus lipid layer relative reflectance spectrum using a wavelength-dependent optical interferometer; converting the measured tear film aqueous plus lipid layer relative reflectance spectrum to a calculated absolute reflectance spectrum; comparing the calculated absolute reflectance spectrum to a theoretical absolute lipid reflectance spectrum to determine a tear film lipid layer thickness; and determining a reflectivity value for the tear film lipid layer thickness at a first wavelength of light corresponding to ultraviolet, violet, or blue light.

Abstract: A method for determining reflectivity of a tear film lipid layer of a patient and recommending a course of treatment based on the same. The method includes the steps of: measuring a tear film aqueous plus lipid layer relative reflectance spectrum using a wavelength-dependent optical interferometer; converting the measured tear film aqueous plus lipid layer relative reflectance spectrum to a calculated absolute reflectance spectrum; comparing the calculated absolute reflectance spectrum to a theoretical absolute lipid reflectance spectrum to determine a tear film lipid layer thickness; and determining a reflectivity value for the tear film lipid layer thickness at a first wavelength of light corresponding to ultraviolet, violet, or blue light.

Abstract: A method for determining reflectivity of a tear film lipid layer of a patient and recommending a course of treatment based on the same. The method includes the steps of: measuring a tear film aqueous plus lipid layer relative reflectance spectrum using a wavelength-dependent optical interferometer; converting the measured tear film aqueous plus lipid layer relative reflectance spectrum to a calculated absolute reflectance spectrum; comparing the calculated absolute reflectance spectrum to a theoretical absolute lipid reflectance spectrum to determine a tear film lipid layer thickness; and determining a reflectivity value for the tear film lipid layer thickness at a first wavelength of light corresponding to ultraviolet, violet, or blue light.

Abstract: A method for determining reflectivity of a tear film lipid layer of a patient and recommending a course of treatment based on the same. The method includes the steps of: measuring a tear film aqueous plus lipid layer relative reflectance spectrum using a wavelength-dependent optical interferometer; converting the measured tear film aqueous plus lipid layer relative reflectance spectrum to a calculated absolute reflectance spectrum; comparing the calculated absolute reflectance spectrum to a theoretical absolute lipid reflectance spectrum to determine a tear film lipid layer thickness; and determining a reflectivity value for the tear film lipid layer thickness at a first wavelength of light corresponding to ultraviolet, violet, or blue light.

Abstract: A method for determining reflectivity of a tear film lipid layer of a patient and recommending a course of treatment based on the same. The method includes the steps of: measuring a tear film aqueous plus lipid layer relative reflectance spectrum using a wavelength-dependent optical interferometer; converting the measured tear film aqueous plus lipid layer relative reflectance spectrum to a calculated absolute reflectance spectrum; comparing the calculated absolute reflectance spectrum to a theoretical absolute lipid reflectance spectrum to determine a tear film lipid layer thickness; and determining a reflectivity value for the tear film lipid layer thickness at a first wavelength of light corresponding to ultraviolet, violet, or blue light.

Abstract: A method for determining optical properties of a corneal region. The method includes the steps of obtaining a combined tear film aqueous layer plus lipid layer thickness; obtaining a tear film lipid layer thickness; subtracting the tear film lipid layer thickness from the combined tear film aqueous layer plus lipid layer thickness to obtain a tear film aqueous layer thickness; and determining a corneal layer refractive index based on the tear film lipid layer thickness and the tear film aqueous layer thickness.

Abstract: A method for determining optical properties of a corneal region. The method includes the steps of obtaining a combined tear film aqueous layer plus lipid layer thickness; obtaining a tear film lipid layer thickness; subtracting the tear film lipid layer thickness from the combined tear film aqueous layer plus lipid layer thickness to obtain a tear film aqueous layer thickness; and determining a corneal layer refractive index based on the tear film lipid layer thickness and the tear film aqueous layer thickness.

Abstract: A method for determining reflectivity of a tear film lipid layer of a patient and recommending a course of treatment based on the same. The method includes the steps of: measuring a tear film aqueous plus lipid layer relative reflectance spectrum using a wavelength-dependent optical interferometer; converting the measured tear film aqueous plus lipid layer relative reflectance spectrum to a calculated absolute reflectance spectrum; comparing the calculated absolute reflectance spectrum to a theoretical absolute lipid reflectance spectrum to determine a tear film lipid layer thickness; and determining a reflectivity value for the tear film lipid layer thickness at a first wavelength of light corresponding to ultraviolet, violet, or blue light.

Abstract: Compositions and methods for disinfecting contact lenses using the compositions are disclosed. The compositions include a combination of alexidine and chlorhexidine, which surprisingly causes the composition to exhibit synergistic antimicrobial activity against Candida albicans by reducing a concentration of Candida albicans by at least 1.2 log.

Abstract: Compositions and methods for disinfecting contact lenses using the compositions are disclosed. The compositions include a combination of alexidine and chlorhexidine, which surprisingly causes the composition to exhibit synergistic antimicrobial activity against Candida albicans by reducing a concentration of Candida albicans by at least 1.2 log.

Abstract: Disclosed herein are stable oil-in-water emulsion ophthalmic topical liquid compositions having an average particle size less than 1 ?m including at least one plant-derived oil other than castor oil wherein the oil comprises only aliphatic side chains free of polar pendent groups. The oil-in-water emulsion ophthalmic topical liquid compositions also include a hydrophilic surfactant having an HLB value between approximately 10 and 14, a vegetable oil-derived hydrophobic non-co-block surfactant having unsaturated side chains that contain less than four oxygen atoms having an HLB value between approximately 4 and 6 and is a liquid at room temperature. The oil-in-water emulsion ophthalmic topical liquid compositions disclosed herein can further include an amount of cyclosporine A or polyphenol in an amount effective to relieve dry eye symptoms.

Abstract: Disclosed herein are ophthalmic cleaning systems and methods for their use, which comprise an ophthalmic solution and lens case, wherein the solution includes dual disinfectants and the lens case includes silver. When the lens case is combined with the solution according to the system of the present invention, it surprisingly exhibits synergistic activity which results in a faster antimicrobial activity.

Abstract: Disclosed herein are ophthalmic cleaning systems and methods for their use, which comprise an ophthalmic solution and lens case, wherein the solution includes dual disinfectants and the lens case includes silver. When the lens case is combined with the solution according to the system of the present invention, it surprisingly exhibits synergistic activity which results in a faster antimicrobial activity.

Abstract: Methods and devices measure eye blinks and tear film lipid and aqueous layer thickness before and following ophthalmic formula application onto the ocular surface, especially wherein the ophthalmic formula is an artificial tear. The methods and devices are suitable for dry eye diagnosis. The methods and devices are suitable for use to evaluate ophthalmic formula effects on the tear film and to use such information to diagnose ophthalmic formula treatment of ocular disease conditions such as dry eye in the absence of contact lens wear or post-surgical eye drop treatment and diagnosis. The methods and devices are also suitable for use in the optimization of ophthalmic drug dosage forms and sustained drug release.

Abstract: Disclosed herein are ophthalmic cleaning systems and methods for their use, which comprise an ophthalmic solution and lens case, wherein the solution includes dual disinfectants and the lens case includes silver. When the lens case is combined with the solution according to the system of the present invention, it surprisingly exhibits synergistic activity which results in a faster antimicrobial activity.

Abstract: Disclosed herein are stable oil-in-water emulsion ophthalmic topical liquid compositions having an average particle size less than 1 ?m including at least one plant-derived oil other than castor oil wherein the oil comprises only aliphatic side chains free of polar pendent groups. The oil-in-water emulsion ophthalmic topical liquid compositions also include a hydrophilic surfactant having an HLB value between approximately 10 and 14, a vegetable oil-derived hydrophobic non-co-block surfactant having unsaturated side chains that contain less than four oxygen atoms having an HLB value between approximately 4 and 6 and is a liquid at room temperature. The oil-in-water emulsion ophthalmic topical liquid compositions disclosed herein can further include an amount of cyclosporine A or polyphenol in an amount effective to relieve dry eye symptoms.

Abstract: A multi-purpose contact lens care solution having high antimicrobial activity comprising, in an aqueous liquid medium, cetylpyridinium chloride and a non-ionic surfactant. In one embodiment of the invention, the non-ionic surfactant is a poly(oxypropylene)-poly(oxyethylene) block copolymer. The solution may optionally also include additional antimicrobial components, a buffer component, a viscosity inducing component, a surfactant, taurine, propylene glycol and/or a tonicity component. This solution additionally prevents losses in ocular tissue membrane integrity during contact lens wear.

Abstract: A multi-purpose contact lens care solution having high antimicrobial activity comprising, in an aqueous liquid medium, cetylpyridinium chloride and a non-ionic surfactant. In one embodiment of the invention, the non-ionic surfactant is a poly(oxypropylene)-poly(oxyethylene) block copolymer. The solution may optionally also include additional antimicrobial components, a buffer component, a viscosity inducing component, a surfactant, taurine, propylene glycol and/or a tonicity component. This solution additionally prevents losses in ocular tissue membrane integrity during contact lens wear.

Abstract: Multi-purpose solutions for contact lens care provide substantial lens wearer/user comfort and/or acceptability, with minimal, if any, corneal epithelial punctate fluorescein staining. Such solutions may include an aqueous liquid medium; an antimicrobial component comprising polyquarternium-1 and a hexamethylene biguanide polymer having a number average molecular weight in the range of from about 4,000 to about 45,000; a surfactant component, preferably a poly(oxyethylene)-poly(oxypropylene) block copolymer surfactant, in an effective amount; a buffer component in an effective amount; a viscosity-inducing component, preferably selected from cellulosic derivatives, in an effective amount; and a tonicity component in an effective amount. Such solutions have substantial performance, comfort and acceptability benefits, which, ultimately, lead to ocular health advantages and avoidance of problems caused by contact lens wear.

Abstract: The present compositions advantageously treat hyperemia with substantially no added irritation to the eye. In one embodiment, the compositions include an ophthalmically acceptable carrier component, a vasoconstrictor component in an amount effective to treat hyperemia when the composition is administered to an eye, and a polyanionic component in an amount effective to provide lubrication to an eye when the compositions are administered to the eye.